Director share purchases

November 7, 2022

LungLife AI, Inc.
(the “Company” or “LungLife”)

Director share purchases

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors.

On 2 November 2022, Paul Pagano, Chief Executive Officer, purchased 5,000 Common Shares at a price of 130 pence per share. Following this purchase, Paul Pagano now holds 5,000 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

In addition, on 2 November 2022, David Anderson, Chief Financial Officer, purchased 5,000 Common Shares at a price of 130 pence per share. Following this purchase, David Anderson now holds 5,000 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

For the full announcement, click HERE. 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

1.Details of the person discharging managerial responsibilities / person closely associated
a)NamePaul Pagano
2.Reason for the Notification
a)Position/statusChief Executive Officer
b)Initial notification/amendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameLungLife AI, Inc
b)LEI549300VBVDIF0Y3OVI38
4.Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a)Description of the Financial instrument, type of instrument, identification codeCommon shares of $0.0001 each in the capital of the Company

ISIN: USU5500L1045

b)Nature of the TransactionPurchase of Common Shares
c)Price(s) and volume(s)
PriceVolume
130 pence5,000
d)Aggregated information

-     Aggregated volume

-     Price

As above
e)Date of the transaction2/11/2022
f)Place of the transactionLondon Stock Exchange

 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

1.Details of the person discharging managerial responsibilities / person closely associated
a)NameDavid Anderson
2.Reason for the Notification
a)Position/statusChief Financial Officer
b)Initial notification/amendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameLungLife AI, Inc
b)LEI549300VBVDIF0Y3OVI38
4.Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a)Description of the Financial instrument, type of instrument, identification codeCommon shares of $0.0001 each in the capital of the Company

ISIN: USU5500L1045

b)Nature of the TransactionPurchase of Common Shares
c)Price(s) and volume(s)
PriceVolume
130 pence5,000
d)Aggregated information

-     Aggregated volume

-     Price

As above
e)Date of the transaction2/11/2022
f)Place of the transactionLondon Stock Exchange

 

 

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down